YU11402A - Nova primena docetaksela za lečenje hepatoma - Google Patents

Nova primena docetaksela za lečenje hepatoma

Info

Publication number
YU11402A
YU11402A YU11402A YUP11402A YU11402A YU 11402 A YU11402 A YU 11402A YU 11402 A YU11402 A YU 11402A YU P11402 A YUP11402 A YU P11402A YU 11402 A YU11402 A YU 11402A
Authority
YU
Yugoslavia
Prior art keywords
docetaxel
new use
treating hepatoma
hepatoma
treating
Prior art date
Application number
YU11402A
Other languages
English (en)
Inventor
Chin-Wen Chi
Heng-Liang Lin
Tsung-Yun Liu
Wing-Yiu Lui
Gar-Yang Chau
Original Assignee
Aventis Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma S.A. filed Critical Aventis Pharma S.A.
Publication of YU11402A publication Critical patent/YU11402A/sh
Publication of RS50148B publication Critical patent/RS50148B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Ovaj pronalazak se zasniva na nalazu da je docetaksel znatno aktivniji protiv ćelija hepatoćelijskih karcinoma od paklitaksela pri koncentracijama do 1ВµM. Prema tome ovaj pronalazak daje primenu docetaksela ili njegovog hidrata u proizvodnji leka za primenu u lečenju hepatoćelijskog karcinoma.[The present invention is based on the finding that docetaxel is significantly more active against hepatocellular carcinoma cells than paclitaxel at concentrations of up to 1ВµM. It accordingly provides the use of docetaxel, or a hydrate thereof, in the manufacture of a medicament for use in the treatment of hepatocellular carcinoma.
YUP-114/02A 1999-08-31 2000-08-29 Upotreba docetaksela za lečenje hepatoćelijskog karcinoma RS50148B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9920548.6A GB9920548D0 (en) 1999-08-31 1999-08-31 Treatment of hepatocellular carcinoma

Publications (2)

Publication Number Publication Date
YU11402A true YU11402A (sh) 2005-07-19
RS50148B RS50148B (sr) 2009-05-06

Family

ID=10860081

Country Status (34)

Country Link
US (2) US20030158249A1 (sh)
EP (1) EP1214061B1 (sh)
JP (1) JP4866522B2 (sh)
KR (1) KR100670416B1 (sh)
CN (1) CN1174748C (sh)
AT (1) ATE269700T1 (sh)
AU (1) AU777583B2 (sh)
BG (1) BG65913B1 (sh)
BR (1) BR0013625A (sh)
CA (1) CA2382294C (sh)
CZ (1) CZ301378B6 (sh)
DE (1) DE60011794T2 (sh)
DK (1) DK1214061T3 (sh)
EA (1) EA004804B1 (sh)
EE (1) EE05124B1 (sh)
ES (1) ES2218223T3 (sh)
GB (1) GB9920548D0 (sh)
HK (1) HK1048944B (sh)
HR (1) HRP20020171A2 (sh)
HU (1) HU228861B1 (sh)
IL (2) IL147489A0 (sh)
ME (1) MEP7809A (sh)
MX (1) MXPA02002041A (sh)
NO (1) NO328527B1 (sh)
NZ (1) NZ517604A (sh)
PL (1) PL212612B1 (sh)
PT (1) PT1214061E (sh)
RS (1) RS50148B (sh)
SI (1) SI1214061T1 (sh)
SK (1) SK286378B6 (sh)
TW (1) TW589180B (sh)
UA (1) UA72927C2 (sh)
WO (1) WO2001015675A2 (sh)
ZA (1) ZA200201408B (sh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1268619C (zh) 2003-05-08 2006-08-09 上海迪赛诺化学制药有限公司 多烯紫杉醇三水化合物的制备方法
EP1694660B1 (en) * 2003-12-12 2009-04-08 Quiral Quimica Do Brasil Process for the preparation of anhydrous and hydrated active pharmaceutical ingredients (apis); stable pharmaceutical compositions prepared from the same and uses of said compositions
US7449196B2 (en) * 2004-07-09 2008-11-11 Robert Sabin Anti tumor compositions and methods of use
RU2451510C2 (ru) * 2005-08-31 2012-05-27 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Композиции и способы получения слаборастворимых в воде лекарственных средств с увеличенной стабильностью
BRPI0615292A8 (pt) 2005-08-31 2018-03-06 Abraxis Bioscience Llc composições e métodos para preparação de fármacos de má solubilidade em água com estabilidade aumentada
US9839667B2 (en) 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
US20080081051A1 (en) * 2006-09-28 2008-04-03 Robert Sabin Method of manufacturing anti-tumor and anti-viral compositions
CA2683712A1 (en) * 2007-04-20 2009-01-15 Sun Pharmaceutical Industries Limited Pharmaceutical compositions
FR2917088B1 (fr) * 2007-06-08 2009-09-04 Aventis Pharma Sa Dissolution directe du docetaxel dans un solvant dans le polysorbate 80
US8541360B2 (en) * 2008-11-19 2013-09-24 Ben Venue Laboratories, Inc. Parenteral formulations comprising sugar-based esters and ethers
CA3051495A1 (en) 2010-03-26 2011-09-29 Abraxis Bioscience, Llc Use of nanoparticles comprising a taxane and albumin in the treatment of hepatocellular carcinoma
KR101752944B1 (ko) * 2010-05-03 2017-07-03 테이코쿠 팔마 유에스에이, 인코포레이티드 비수성의 탁산 프로에멀젼 제제, 및 그의 제조 및 사용 방법
US8842114B1 (en) 2011-04-29 2014-09-23 Nvidia Corporation System, method, and computer program product for adjusting a depth of displayed objects within a region of a display
JO3685B1 (ar) * 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
CA2976912A1 (en) * 2015-02-17 2016-08-25 Mallinckrodt Llc Modified docetaxel liposome formulations and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2629819B1 (fr) * 1988-04-06 1990-11-16 Rhone Poulenc Sante Procede de preparation de derives de la baccatine iii et de la desacetyl-10 baccatine iii
US5543154A (en) * 1991-12-27 1996-08-06 Merck & Co., Inc. Controlled release nifedipine delivery device
EP0680320B1 (en) * 1993-01-19 1999-04-14 Warner-Lambert Company Stable oral ci-981 formulation and process of preparing same
US5846945A (en) * 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5436243A (en) * 1993-11-17 1995-07-25 Research Triangle Institute Duke University Aminoanthraquinone derivatives to combat multidrug resistance
FR2718963B1 (fr) * 1994-04-25 1996-05-24 Rhone Poulenc Rorer Sa Nouvelle composition pharmaceutique à base de taxoïdes.
FR2722191B1 (fr) * 1994-07-08 1996-08-23 Rhone Poulenc Rorer Sa Procede de preparation du trihydrate du (2r,3s)-3-tertbutoxycarbonylamino-2-hydroxy-3-phenylpropionate de 4-acetoxy2alpha-benzoyloxy-5beta,20epoxy-1,7beta,10beta trihydroxy-9-oxo-tax-11-en-13alpha-yle
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US5968972A (en) 1995-10-26 1999-10-19 Baker Norton Pharmaceuticals, Inc. Method for increasing the oral bioactivity of pharmaceutical agents
FR2742751B1 (fr) * 1995-12-22 1998-01-30 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
US6503893B2 (en) * 1996-12-30 2003-01-07 Bone Care International, Inc. Method of treating hyperproliferative diseases using active vitamin D analogues
CA2628857C (en) * 1996-12-30 2011-09-13 Batelle Memorial Institute Formulation and method for treating neoplasms by inhalation
EP1023050B1 (en) * 1997-06-27 2013-09-25 Abraxis BioScience, LLC Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
JP3775780B2 (ja) * 1997-09-18 2006-05-17 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 薬剤の経口的バイオアベイラビリテイを向上させるための縮合イミダゾール誘導体
JP4738592B2 (ja) * 1997-10-31 2011-08-03 アーチ・デヴェロップメント・コーポレイション ５α−還元酵素活性を調節するための方法及び組成物
UA73092C2 (uk) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
BR9916536A (pt) * 1998-12-23 2002-01-02 Searle & Co Método para o tratamento ou prevenção de um distúrbio de neoplasia em um mamìfero em necessidade deste tratamento ou prevenção, e, combinação
GB9909925D0 (en) * 1999-04-29 1999-06-30 Pharmacia & Upjohn Spa Combined preparations comprising anthracycline derivatives
US8080672B2 (en) * 2005-12-13 2011-12-20 Teva Pharmaceutical Industries Ltd. Crystal form of atorvastatin hemi-calcium and processes for preparation thereof

Also Published As

Publication number Publication date
EE05124B1 (et) 2009-02-16
IL147489A0 (en) 2002-08-14
DE60011794D1 (de) 2004-07-29
PT1214061E (pt) 2004-09-30
SK286378B6 (sk) 2008-08-05
TW589180B (en) 2004-06-01
HUP0203197A2 (hu) 2003-01-28
HU228861B1 (hu) 2013-06-28
ES2218223T3 (es) 2004-11-16
PL353198A1 (en) 2003-11-03
BG106460A (bg) 2002-09-30
KR20020060166A (ko) 2002-07-16
WO2001015675A2 (en) 2001-03-08
ZA200201408B (en) 2003-07-30
CN1174748C (zh) 2004-11-10
WO2001015675A3 (en) 2001-09-20
DK1214061T3 (da) 2004-11-01
EP1214061B1 (en) 2004-06-23
PL212612B1 (pl) 2012-10-31
HK1048944B (zh) 2005-04-22
CN1372466A (zh) 2002-10-02
EE200200087A (et) 2003-04-15
IL147489A (en) 2006-06-11
ME00624B (me) 2011-12-20
SK2712002A3 (en) 2002-07-02
MEP7809A (en) 2011-12-20
EA200200313A1 (ru) 2002-08-29
CA2382294A1 (en) 2001-03-08
NZ517604A (en) 2004-04-30
ATE269700T1 (de) 2004-07-15
AU7516800A (en) 2001-03-26
AU777583B2 (en) 2004-10-21
KR100670416B1 (ko) 2007-01-17
NO20020829L (no) 2002-02-20
CZ2002739A3 (cs) 2002-06-12
EA004804B1 (ru) 2004-08-26
HK1048944A1 (en) 2003-04-25
MXPA02002041A (es) 2002-08-20
CZ301378B6 (cs) 2010-02-03
NO20020829D0 (no) 2002-02-20
JP4866522B2 (ja) 2012-02-01
BR0013625A (pt) 2002-05-14
HRP20020171A2 (en) 2004-02-29
CA2382294C (en) 2008-06-03
US20080045584A1 (en) 2008-02-21
BG65913B1 (bg) 2010-05-31
SI1214061T1 (en) 2004-12-31
DE60011794T2 (de) 2005-07-14
NO328527B1 (no) 2010-03-08
RS50148B (sr) 2009-05-06
US20030158249A1 (en) 2003-08-21
GB9920548D0 (en) 1999-11-03
UA72927C2 (uk) 2005-05-16
JP2003508427A (ja) 2003-03-04
EP1214061A2 (en) 2002-06-19
HUP0203197A3 (en) 2005-01-28

Similar Documents

Publication Publication Date Title
YU11402A (sh) Nova primena docetaksela za lečenje hepatoma
MXPA05013642A (es) Composicion de un antagonista de vegf y un agente antiproliferativo y su uso para el tratamiento de cancer.
IL192181A0 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder
NO20034204L (no) Farmasöytiske kombinasjoner til behandling av kreft
GB0223038D0 (en) Therapeutic compounds
MX349188B (es) Sns - 595 y metodos para utilizar el mismo.
WO2006029036A3 (en) Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
AU7862401A (en) Pharmaceutical compostion comprising trkaig2 for use in the prevention and/or treatment of cancer
NZ528164A (en) Use of flumazenil to produce a medicament for the treatment of ***e dependency
SI1603584T1 (sl) Aplidin za zdravljenje multiple mieloma
WO2005094282A3 (en) Combination therapy comprising cloretazinetm
UA32314A (uk) Спосіб лікування некротичного панкреатиту
MXPA05002477A (es) Asialo-interferones y el tratamiento de cancer de higado.
UA95094C2 (ru) Применение бензоконденсированных гетероциклических сульфамидных производных для лечения маниакального синдрома и биполярного расстройства
ATE319443T1 (de) Prävention oder behandlung von brust-, prostata- und/oder gebärmutterhalskrebs mit n,n- dimethylglycin
MXPA04003673A (es) Uso de aplidina para el tratamiento de cancer pancreatico.